bpc-157 human clinical trials evidence safety fda warning letter unapproved new drug Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022 BPC-157 and the Difference Between

Specifically, eligible studies included participants (P) with a confirmed diagnosis of vitamin B12 deficiency, interventions (I) involving oral or sublingual vitamin B12 administration, comparators (C) using intramuscular supplementation, and outcomes (O) reporting changes in serum vitamin B12 or homocysteine levels

At the end of the day, open, collaborative conversations with your provider help ensure care is tailored to your needs

In animal and early human studies, it has been shown to: Accelerate tendon and ligament healing making it especially relevant for plantar fascia and Achilles injuries

Source References CNBC, November 21, 2025